Plasma neurofilament light significantly decreases following treatment in Lyme neuroborreliosis and is not associated with persistent symptoms

Currently there is an unmet need for a highly standardized blood biomarker test to monitor treatment response in Lyme neuroborreliosis (LNB). Differentiating between active or past infection is challenged by the relatively high frequency of persistent symptoms after the end of antibiotic treatment (estimated 15%–20%), the variable clinical course and the long‐lasting Borrelia burgdorferi antibodies. The aim was therefore to evaluate plasma neurofilament light chain (pNfL) as a marker for disease activity in LNB.

[1]  K. Blennow,et al.  Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years , 2022, Brain communications.

[2]  P. Calabresi,et al.  Contributors to Serum NfL Levels in People without Neurologic Disease , 2022, Annals of neurology.

[3]  K. Blennow,et al.  Neurofilament Light in Cerebrospinal Fluid is Associated With Disease Staging in European Lyme Neuroborreliosis , 2022, Journal of central nervous system disease.

[4]  C. Enzinger,et al.  Factors influencing serum neurofilament light chain levels in normal aging , 2021, Aging.

[5]  L. Joosten,et al.  Prevalence of persistent symptoms after treatment for lyme borreliosis: A prospective observational cohort study , 2021, The Lancet regional health. Europe.

[6]  D. Arnold,et al.  Serum neurofilament light as a biomarker in progressive multiple sclerosis , 2020, Neurology.

[7]  H. Zetterberg,et al.  Neurofilaments in progressive multiple sclerosis: a systematic review , 2020, Journal of Neurology.

[8]  P. Matthews,et al.  Neurofilaments: neurobiological foundations for biomarker applications. , 2020, Brain : a journal of neurology.

[9]  M. Storgaard,et al.  Lyme neuroborreliosis in adults: A nationwide prospective cohort study. , 2020, Ticks and tick-borne diseases.

[10]  C. Enzinger,et al.  Serum neurofilament light levels in normal aging and their association with morphologic brain changes , 2020, Nature Communications.

[11]  K. Blennow,et al.  Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. , 2019, JAMA neurology.

[12]  N. Speybroeck,et al.  Combining primary care surveillance and a meta-analysis to estimate the incidence of the clinical manifestations of Lyme borreliosis in Belgium, 2015-2017. , 2019, Ticks and tick-borne diseases.

[13]  T. Blanchon,et al.  Epidemiology of Lyme borreliosis through two surveillance systems: the national Sentinelles GP network and the national hospital discharge database, France, 2005 to 2016 , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  H. Wilking,et al.  Incidence of notified Lyme borreliosis in Germany, 2013–2017 , 2018, Scientific Reports.

[15]  T. G. Jensen,et al.  Characteristics and Clinical Outcome of Lyme Neuroborreliosis in a High Endemic Area, 1995-2014: A Retrospective Cohort Study in Denmark. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Henrik Zetterberg,et al.  Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration , 2016, Neuron.

[17]  R. Dessau,et al.  Improving national surveillance of Lyme neuroborreliosis in Denmark through electronic reporting of specific antibody index testing from 2010 to 2012. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[18]  V. Fingerle,et al.  EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis , 2010, European journal of neurology.

[19]  E. Skogvoll,et al.  Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial , 2008, The Lancet Neurology.

[20]  A. Lebech,et al.  The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. , 1992, Brain : a journal of neurology.

[21]  A. Lebech,et al.  Lyme neuroborreliosis: A new sensitive diagnostic assay for intrathecal synthesis of borrelia burgdorferi–specific immunoglobulin G, A, and M , 1991, Annals of neurology.

[22]  J. Trojanowski,et al.  Expression of neurofilament subunits in neurons of the central and peripheral nervous system: an immunohistochemical study with monoclonal antibodies , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  C. Crone,et al.  Lyme neuroborreliosis. , 2013, Handbook of clinical neurology.